|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.19/-0.99
|
企業價值
2.68M
|
資產負債 |
每股賬面淨值
-0.25
|
現金流量 |
現金流量率
--
|
損益表 |
收益
58.47K
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/16 23:45 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |